Contineum Therapeutics, Inc. Class A Common Stock (CTNM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a cash flow conversion efficiency ratio of -0.065x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.27 Million) by net assets ($250.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Contineum Therapeutics, Inc. Class A Com balance sheet independence to measure how much of total assets are equity-financed.
Contineum Therapeutics, Inc. Class A Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Contineum Therapeutics, Inc. Class A Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CTNM cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Contineum Therapeutics, Inc. Class A Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Contineum Therapeutics, Inc. Class A Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhuhai Rundu Pharmaceutical Co Ltd Class A
SHE:002923
|
0.036x |
|
Jiangsu United Water Technology Co. Ltd. Cl A
SHG:603291
|
N/A |
|
Shenzhen Aoto Electronics Co Ltd
SHE:002587
|
0.013x |
|
MSC Income Fund, Inc.
NYSE:MSIF
|
0.019x |
|
Jay Mart Public Company Limited
BK:JMART
|
0.025x |
|
Guangdong Piano Customized Furniture Co Ltd
SHE:002853
|
0.016x |
|
Cachet Pharmaceutical Co Ltd
SHE:002462
|
0.078x |
|
Dada Nexus Ltd
NASDAQ:DADA
|
0.009x |
Annual Cash Flow Conversion Efficiency for Contineum Therapeutics, Inc. Class A Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Contineum Therapeutics, Inc. Class A Common Stock from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Contineum Therapeutics, Inc. Class A Com.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $260.99 Million | $-55.31 Million | -0.212x | -27.80% |
| 2024-12-31 | $198.07 Million | $-32.84 Million | -0.166x | +41.78% |
| 2023-12-31 | $-67.94 Million | $19.35 Million | -0.285x | +44.41% |
| 2022-12-31 | $39.27 Million | $-20.12 Million | -0.512x | -20.14% |
| 2021-12-31 | $61.59 Million | $-26.27 Million | -0.426x | -- |
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibr… Read more